Stage Iii Non-small Cell Lung Cancer: Disease Bioinformatics
Lung cancer begins in the lungs and has become the leading cause of cancer deaths in the United States for both men and women--claiming more lives than colon, ovarian, prostate, and breast cancer combined. There are two types of lung cancer: small and non-small based on the appearance of the cancer cells on the microscope. Non-small cell lung cancer accounts for approximately 85% of lung cancers and include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Risk for being diagnosed with lung cancer includes smoking, second hand smoke, exposure to radon gas, asbestos, and other chemicals, excessive alcohol use, and a family history. Treatments depend on the stage as well as type of lung cancer but include: surgery, chemotherapy, radiation, targeted drug therapy, and clinical trials. Stage III non-small cell lung cancer can be divided into IIIA as well as IIIB. Differences between IIIA and IIIB may change treatment plans.
Top Research Reagents
We have 4383 products for the study of Stage Iii Non-small Cell Lung Cancer that can be applied to Chromatin Immunoprecipitation, Chromatin Immunoprecipitation (ChIP), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot from our catalog of antibodies and ELISA kits.
Stage Iii Non-small Cell Lung Cancer is also known as Non-small Cell Lung Cancer Stage Iii, Non-small Cell Lung Cancer, Stage Iii, Nsclc, Stage Iii, Stage Iii Non-small Cell Carcinoma Of The Lung, Stage Iii Non-small Cell Lung Carcinoma.